eXoZymes, Inc. (EXOZ) Stock Score, Valuation & Financial Research

eXoZymes, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for EXOZ

eXoZymes, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.52. These figures are a research snapshot, not a buy or sell recommendation.

What eXoZymes, Inc. does

eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

eXoZymes is a pre-revenue, development-stage biotechnology company that aims to commercialize its proprietary exozyme-based biomanufacturing platform through spinouts, joint ventures, and licensing agreements. The company seeks to partner with entities possessing relevant manufacturing infrastructure to share the costs, risks, and potential future revenues associated with deploying its engineered enzyme solutions for specific market applications.

Products and services

  • The company develops exozymes, which are advanced enzymes engineered using artificial intelligence and bioengineering to function in bioreactors outside of living cells, designed to convert feedstocks into valuable chemicals.

Competitors and product-market comparisons

  • Debut Biotech — A company that promotes the advantages of cell-free enzymatic biomanufacturing. Source
  • Solugen Inc. — A company that promotes the advantages of cell-free enzymatic biomanufacturing. Source

Business risks and research considerations

  • Pre-revenue development stage status and history of operating losses Source
  • Lack of history in manufacturing, product development, or marketing Source

Sources: Company research source · Lack of history in manufacturing, product development, or marketing

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

EXOZ financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 5.52
Market capitalization:
51.23M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -10.19M
Free cash flow:
USD -6.67M
Cash:
USD 5.65M
Total debt:
USD 1.09M
EPS:
USD -1.20

What stands out

  • Free cash flow is USD -6.67M, negative for the stored period.
  • The balance sheet shows USD 5.65M of cash versus USD 1.09M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for EXOZ

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can EXOZ fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is EXOZ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for EXOZ to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of EXOZ's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research EXOZ

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.